ACLY and chronic kidney disease: Meta-analysis of the primary CKD phenotype across UK Biobank, CKDGen, and FinnGen data including 66,396 CKD cases and 958,517 controls revealed a significant association between reduced ACLY expression and reduced risk of CKD (OR = 0.91, 95% CI: 0.85–0.98 per 34% relative reduction in ACLY eQTL genetic instrument; P = 0.008; Figure 2 and Supplementary Figure S1).